These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1506127)

  • 21. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vivo verification of in vitro release specifications of a theophylline sustained-release preparation].
    von Nieciecki A; Fuchs WS; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):580-3. PubMed ID: 9676348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.
    Steinijans VW; Dietrich R; Trautmann H; Sauter R; Benedikt G
    Arzneimittelforschung; 1988 Aug; 38(8A):1238-40. PubMed ID: 3190812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of manuscript reviews in nursing research.
    Henly SJ; Dougherty MC
    Nurs Outlook; 2009; 57(1):18-26. PubMed ID: 19150263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An approach to select the appropriate statistical method for testing bioequivalence.
    Steyn HS; Koeleman HA; Gouws E; Ritschel WA
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):156-60. PubMed ID: 1822089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asthma management: the challenge of equivalence.
    Steinijans VW; Neuhäuser M; Hummel T; Leichtl S; Rathgeb F; Keller A
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):117-25. PubMed ID: 9562226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does presentation at the Registrars' Papers Day predict future publication?
    Wong SW; Crowe PJ
    ANZ J Surg; 2006 Jun; 76(6):522-5. PubMed ID: 16768782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A two-stage procedure for bioequivalence studies.
    Racine-Poon A; Grieve AP; Flühler H; Smith AF
    Biometrics; 1987 Dec; 43(4):847-56. PubMed ID: 3427169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the assessment of bioequivalence in a two-period cross-over design.
    Wijnand HP
    Comput Methods Programs Biomed; 1992 Mar; 37(2):151-7. PubMed ID: 1643857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Including information on the therapeutic window in bioequivalence acceptance.
    Jacobs T; De Ridder F; Rusch S; Van Peer A; Molenberghs G; Bijnens L
    Pharm Res; 2008 Nov; 25(11):2628-38. PubMed ID: 18636320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Which is the best test for my data?].
    Berger U
    Psychother Psychosom Med Psychol; 2010 Nov; 60(11):457-8. PubMed ID: 21072723
    [No Abstract]   [Full Text] [Related]  

  • 35. [Does statistical data presentation influence perception?].
    Krome S
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1242. PubMed ID: 21630169
    [No Abstract]   [Full Text] [Related]  

  • 36. The quantitative research of composite immune indicator for crustacean.
    Ma Z; Zhao J; Wu L; Shi C; Zhang C
    Fish Shellfish Immunol; 2010 Jan; 28(1):187-92. PubMed ID: 19874895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of the estimands framework for clinical pharmacology trials: Some discussion points.
    Ring A; Wolfsegger MJ
    Br J Clin Pharmacol; 2020 Jul; 86(7):1240-1247. PubMed ID: 32030776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When is a metric not a metric? Remarks on direct curve comparison in bioequivalence studies.
    Jawień W
    J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):261-79. PubMed ID: 19544090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment on: Updates of bioequivalence programs (including statistical power approximated by Student's t).
    Hauschke D
    Comput Methods Programs Biomed; 1995 Jun; 47(1):93-4. PubMed ID: 7554866
    [No Abstract]   [Full Text] [Related]  

  • 40. Commentary on individual bioequivalence by M.-L. Chen.
    Hauck WW; Anderson S
    J Biopharm Stat; 1997 Mar; 7(1):13-6. PubMed ID: 9056582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.